IDH1 and cancer: Through a survey of more than 45,000 pan-cancer samples, we observed that IDH1 and IDH2 hotspot mutations are uncommon (2%) and extremely rare (0.4%), respectively, in human cancer, a finding in agreement with an independent pan-cancer analysis [37].